$7.23 0.5 7.7%
Last Trade - 4:06pm
| Market Cap | £918.0m |
| Enterprise Value | £902.0m |
| Revenue | £31.0k |
| Position in Universe | 2615th / 6848 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.043 | 452.3 | 858 | |||
| +81.1 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | July 14, 2006 |
| Public Since | December 3, 2014 |
| No. of Shareholders: | 21 |
| No. of Employees: | 15 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 188,088,860 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 5 Great Valley Pkwy Ste 160, MALVERN, 19355-1445, United States |
| Web | http://www.histogenics.com/ |
| Phone | +1 484 3284698 |
| Contact | Kelly Beck (Vice President, Investor Relations and Administration and Corporate Secretary) |
| Auditors | Ernst & Young LLP |
As of 4:06pm, shares in Ocugen Inc are trading at $7.23, giving the company a market capitalisation of £918.0m. This share price information is delayed by 15 minutes.
Shares in Ocugen Inc are currently trading at $7.23 and the price has moved by 2.02k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ocugen Inc price has moved by 1.36k% over the past year.
Of the analysts with advisory recommendations for Ocugen Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ocugen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Ocugen Inc is scheduled to issue upcoming financial results on the following dates:
Ocugen Inc does not currently pay a dividend.
Ocugen Inc does not currently pay a dividend.
Ocugen Inc does not currently pay a dividend.
To buy shares in Ocugen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Ocugen Inc are currently trading at $7.23, giving the company a market capitalisation of £918.0m.
Here are the trading details for Ocugen Inc:
Based on an overall assessment of its quality, value and momentum, Ocugen Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Ocugen Inc are currently priced at $7.23. At that level they are trading at 34.13% discount to the analyst consensus target price of 0.00.
Analysts covering Ocugen Inc currently have a consensus Earnings Per Share (EPS) forecast of 2.195 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ocugen Inc. Over the past six months, the relative strength of its shares against the market has been 1.64k%. At the current price of $7.23, shares in Ocugen Inc are trading at 0.160k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Ocugen Inc.
Ocugen Inc's management team is headed by:
Here are the top five shareholders of Ocugen Inc based on the size of their shareholding:
